A bill to require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible.

This bill, introduced in the 119th Congress as S.4332 on April 16, 2026, aims to mandate the Secretary of Health and Human Services to assess the exclusivity periods applicable to licensed biological products, specifying the eligibility criteria for such periods.